FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth

Cancer Research

Volumn 71, Issue 3, 2011, Pages 914-924

  Brooke, Greg N ^a   Culley, Rachel L ^a   Dart, D Alwyn ^a   Mann, David J ^b   Gaughan, Luke ^e   McCracken, Stuart R ^e   Robson, Craig N ^e   Spencer Dene, Bradley ^c   Gamble, Simon C ^a   Powell, Sue M ^a   Wait, Robin ^d   Waxman, Jonathan ^a   Walker, Marjorie M ^d   Bevan, Charlotte L ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Faculty of Natural Sciences   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CYCLIN D1; CYCLIN DEPENDENT KINASE 6; FUSED IN EWING SARCOMA TRANSLOCATED IN LIPOSARCOMA; PROTEIN P27; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GLEASON SCORE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; SURVIVAL RATE; SURVIVAL TIME; TUMOR REGRESSION; TUMOR XENOGRAFT;

BONE NEOPLASMS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NANDROLONE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA-BINDING PROTEIN FUS;

EID: 79551547450     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0874     Document Type: Article

References (26)

1. Cifuentes E, Croxen R, Menon M, Barrack ER, Reddy GP. Synchronized prostate cancer cells for studying androgen regulated events in cell cycle progression from G1 into S phase. J Cell Physiol 2003;195:337-45. (Pubitemid 36529862)
2. Knudsen KE, Arden KC, Cavenee WK. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem 1998;273:20213-22.
3. Chen Y, Robles AI, Martinez LA, Liu F, Gimenez-Conti IB, Conti CJ. Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ 1996;7:1571-8. (Pubitemid 26378352)
4. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
5. Law WJ, Cann KL, Hicks GG. TLS, EWS and TAF15: a model for transcriptional integration of gene expression. Brief Funct Genomic Proteomic 2006;5:8-14.
6. Morohoshi F, Ootsuka Y, Arai K, Ichikawa H, Mitani S, Munakata N, et al. Genomic structure of the human RBP56/hTAFII68 and FUS/TLS genes. Gene 1998;221:191-8. (Pubitemid 29023746)
7. Rabbitts TH, Forster A, Larson R, Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993;4:175-80.
8. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993;363:640-4.
9. Meissner M, Lopato S, Gotzmann J, Sauermann G, Barta A. Protooncoprotein TLS/FUS is associated to the nuclear matrix and complexed with splicing factors PTB, SRm160, and SR proteins. Exp Cell Res 2003;283:184-95. (Pubitemid 36269024)
10. Hicks GG, Singh N, Nashabi A, Mai S, Bozek G, Klewes L, et al. Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat Genet 2000;24:175-9.
11. Andersson MK, Stahlberg A, Arvidsson Y, Olofsson A, Semb H, Stenman G, et al. The multifunctional FUS, EWS and TAF15 protooncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biol 2008;9:37.
12. Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, et al. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature 2008;454:126-30.
13. Tan AY, Manley JL. TLS inhibits RNA polymerase III transcription. Mol Cell Biol 2010;30:186-96.
14. Gamble SC, Odontiadis M, Waxman J, Westbrook JA, Dunn MJ, Wait R, et al. Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene 2004;23:2996-3-004.
15. Kawano Y, Kitaoka M, Hamada Y, Walker MM, Waxman J, Kypta RM. Regulation of prostate cell growth and morphogenesis by Dickkopf-3. Oncogene 2006;25:6528-37. (Pubitemid 44607085)
16. Chang GT, Gamble SC, Jhamai M, Wait R, Bevan CL, Brinkmann AO. Proteomic analysis of proteins regulated by TRPS1 transcription factor in DU145 prostate cancer cells. Biochim Biophys Acta 2007;1774:575-82.
17. Gamble SC, Chotai D, Odontiadis M, Dart DA, Brooke GN, Powell SM, et al. Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene 2007;26:1757-68.
18. Brooke GN, Parker MG, Bevan CL. Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene 2008;27:2941-50.
19. Clark EL, Coulson A, Dalgliesh C, Rajan P, Nicol SM, Fleming S, et al. The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res 2008;68:7938-46.
20. Dart DA, Spencer-Dene B, Gamble SC, Waxman J, Bevan CL. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours. Endocr Relat Cancer 2009;16:1157-69.
21. Perrotti D, Iervolino A, Cesi V, Cirinná M, Lombardini S, Grassilli E, et al. BCR-ABL prevents c-jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase CbetaII-dependent pathway. Mol Cell Biol 2000;20:6159-69.
22. Lanzino M, Sisci D, Morelli C, Garofalo C, Catalano S, Casaburi I, et al. Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells-identification of a novel androgen response element. Nucleic Acids Res 2010;38:5351-65.
23. Xu Y, Chen SY, Ross KN, Balk SP. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res 2006;66:7783-92. (Pubitemid 44289239)
24. Knudsen K, Fribourg AF, Petre C, Wetherill Y. Androgen ediated Regulation of the G1-S Transition in Prostate Cancer. In: Burnstein KL, editor. Steroid Hormones and Cell Cycle Regulation.Norwell, MA: Kluwer Academic Publishers; 2002.91-110.
25. Velasco AM, Gillis KA, Li Y, Brown EL, Sadler TM, Achilleos M, et al. Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 2004;145:3913-24.
26. Knudsen KE, Cavenee WK, Arden KC. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res 1999;59:2297-301.